ProShare Advisors
BEAM icon

ProShare Advisors’s Beam Therapeutics BEAM Stock Holding History

ProShare Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Sell
18,417
-3,528
-16% -$97.9K ﹤0.01% 1142
2025
Q4 		$608K Buy
21,945
+1,991
+10% +$50.8K ﹤0.01% 1033
2025
Q3 		$484K Sell
19,954
-3,408
-15% -$67.8K ﹤0.01% 1126
2025
Q2 		$397K Sell
23,362
-214
-0.9% -$3.73K ﹤0.01% 1251
2025
Q1 		$460K Sell
23,576
-1,870
-7% -$49K ﹤0.01% 1139
2024
Q4 		$631K Buy
25,446
+6,127
+32% +$156K ﹤0.01% 1141
2024
Q3 		$473K Buy
19,319
+4,247
+28% +$110K ﹤0.01% 1168
2024
Q2 		$353K Sell
15,072
-4,439
-23% -$109K ﹤0.01% 1175
2024
Q1 		$645K Buy
19,511
+1,873
+11% +$58.4K ﹤0.01% 948
2023
Q4 		$480K Buy
17,638
+3,399
+24% +$84.4K ﹤0.01% 1062
2023
Q3 		$342K Buy
14,239
+419
+3% +$11.2K ﹤0.01% 1140
2023
Q2 		$441K Buy
13,820
+880
+7% +$28.6K ﹤0.01% 1025
2023
Q1 		$396K Sell
12,940
-1,961
-13% -$77.4K ﹤0.01% 1029
2022
Q4 		$583K Buy
14,901
+1,036
+7% +$46.4K ﹤0.01% 892
2022
Q3 		$661K Buy
13,865
+494
+4% +$28.2K ﹤0.01% 822
2022
Q2 		$516K Sell
13,371
-4,376
-25% -$174K ﹤0.01% 932
2022
Q1 		$1.02M Sell
17,747
-4,156
-19% -$273K ﹤0.01% 916
2021
Q4 		$1.75M Buy
21,903
+304
+1% +$26K ﹤0.01% 803
2021
Q3 		$1.88M Sell
21,599
-1,834
-8% -$184K 0.01% 729
2021
Q2 		$3.02M Buy
23,433
+4,726
+25% +$377K 0.01% 629
2021
Q1 		$1.5M Buy
18,707
+920
+5% +$87.5K ﹤0.01% 796
2020
Q4 		$1.45M Buy
+17,787
New +$875K 0.01% 730

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

ProShare Advisors's BEAM Position: Q1 2026 in Review

ProShare Advisors reduced its Beam Therapeutics (BEAM) stake by 16% in Q1 2026, selling an estimated $97.9K and leaving 18,417 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #1142.

ProShare Advisors first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.02M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • ProShare Advisors held 18,417 shares of Beam Therapeutics worth $439K as of Q1 2026.
  • ProShare Advisors sold 3,528 Beam Therapeutics shares in Q1 2026, an estimated $97.9K.
  • Beam Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1142 holding.
  • ProShare Advisors first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • ProShare Advisors's Beam Therapeutics position peaked at $3.02M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.